

Xingui Tian

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9723688/publications.pdf>

Version: 2024-02-01

54
papers

990
citations

516215

16
h-index

476904

29
g-index

58
all docs

58
docs citations

58
times ranked

1065
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology and clinical presentation of the four human parainfluenza virus types. BMC Infectious Diseases, 2013, 13, 28.	1.3	116
2	Epidemiology of Acute Respiratory Infections in Children in Guangzhou: A Three-Year Study. PLoS ONE, 2014, 9, e96674.	1.1	89
3	Human adenovirus type 7 infection causes a more severe disease than type 3. BMC Infectious Diseases, 2019, 19, 36.	1.3	75
4	Detection of human bocavirus from children and adults with acute respiratory tract illness in Guangzhou, southern China. BMC Infectious Diseases, 2011, 11, 345.	1.3	49
5	Construction and characterization of a replication-competent human adenovirus type 3-based vector as a live-vaccine candidate and a viral delivery vector. Vaccine, 2009, 27, 1145-1153.	1.7	44
6	Comparative genomic analysis of two strains of human adenovirus type 3 isolated from children with acute respiratory infection in southern China. Journal of General Virology, 2006, 87, 1531-1541.	1.3	42
7	Serotype-Specific Neutralizing Antibody Epitopes of Human Adenovirus Type 3 (HAdV-3) and HAdV-7 Reside in Multiple Hexon Hypervariable Regions. Journal of Virology, 2012, 86, 7964-7975.	1.5	38
8	Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon. Virus Research, 2011, 160, 214-220.	1.1	33
9	Retrospective study of adenovirus in autopsied pulmonary tissue of pediatric fatal pneumonia in South China. BMC Infectious Diseases, 2008, 8, 122.	1.3	32
10	Vaccine development for human mastadenovirus. Journal of Thoracic Disease, 2018, 10, S2280-S2294.	0.6	32
11	Protection against Enterovirus 71 with Neutralizing Epitope Incorporation within Adenovirus Type 3 Hexon. PLoS ONE, 2012, 7, e41381.	1.1	31
12	New Epidemiological and Clinical Signatures of 18 Pathogens from Respiratory Tract Infections Based on a 5-Year Study. PLoS ONE, 2015, 10, e0138684.	1.1	27
13	A recombinant trivalent vaccine candidate against human adenovirus types 3, 7, and 55. Vaccine, 2018, 36, 2199-2206.	1.7	27
14	Characterization of a cross-reactive monoclonal antibody against Norovirus genogroups I, II, III and V. Virus Research, 2010, 151, 142-147.	1.1	24
15	Seroprevalence of neutralizing antibodies against adenovirus type 14 and 55 in healthy adults in Southern China. Emerging Microbes and Infections, 2017, 6, 1-8.	3.0	24
16	Hexon and fiber of adenovirus type 14 and 55 are major targets of neutralizing antibody but only fiber-specific antibody contributes to cross-neutralizing activity. Virology, 2018, 518, 272-283.	1.1	20
17	A tetravalent vaccine comprising hexon-chimeric adenoviruses elicits balanced protective immunity against human adenovirus types 3, 7, 14 and 55. Antiviral Research, 2018, 154, 17-25.	1.9	16
18	Broadly neutralizing monoclonal antibodies against human adenovirus types 55, 14p, 7, and 11 generated with recombinant type 11 fiber knob. Emerging Microbes and Infections, 2018, 7, 1-12.	3.0	16

#	ARTICLE	IF	CITATIONS
19	Generation of Neutralizing Monoclonal Antibodies against a Conformational Epitope of Human Adenovirus Type 7 (HAdv-7) Incorporated in Capsid Encoded in a HAdv-3-Based Vector. <i>PLoS ONE</i> , 2014, 9, e103058.	1.1	15
20	Identification and characterization of a native epitope common to norovirus strains GII/4, GII/7 and GII/8. <i>Virus Research</i> , 2009, 140, 188-193.	1.1	14
21	Identification and Application of Neutralizing Epitopes of Human Adenovirus Type 55 Hexon Protein. <i>Viruses</i> , 2015, 7, 5632-5642.	1.5	14
22	Prevalence of neutralizing antibodies to common respiratory viruses in intravenous immunoglobulin and in healthy donors in southern China. <i>Journal of Thoracic Disease</i> , 2016, 8, 803-812.	0.6	13
23	Seroprevalence of Neutralizing Antibodies against Six Human Adenovirus Types Indicates the Low Level of Herd Immunity in Young Children from Guangzhou, China. <i>Virologica Sinica</i> , 2021, 36, 373-381.	1.2	13
24	Analysis of severe human adenovirus infection outbreak in Guangdong Province, southern China in 2019. <i>Virologica Sinica</i> , 2022, 37, 331-340.	1.2	12
25	Identification of a Critical and Conformational Neutralizing Epitope in Human Adenovirus Type 4 Hexon. <i>Journal of Virology</i> , 2018, 92, .	1.5	11
26	Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon. <i>PLoS ONE</i> , 2016, 11, e0156984.	1.1	10
27	Epidemiology and Genetic Variabilities of Human Adenovirus Type 55 Reveal Relative Genome Stability Across Time and Geographic Space in China. <i>Frontiers in Microbiology</i> , 2020, 11, 606195.	1.5	10
28	Chinese tree shrew: a permissive model for in vitro and in vivo replication of human adenovirus species B. <i>Emerging Microbes and Infections</i> , 2021, 10, 424-438.	3.0	9
29	Evaluation of an innovative pediatric isolation (PI) bed using fluid dynamics simulation and aerosol isolation efficacy. <i>Building Simulation</i> , 2021, 14, 1543-1552.	3.0	9
30	Epitope mapping of severe acute respiratory syndrome-related coronavirus nucleocapsid protein with a rabbit monoclonal antibody. <i>Virus Research</i> , 2021, 300, 198445.	1.1	9
31	Construction and characterization of a recombinant human adenovirus type 3 vector containing two foreign neutralizing epitopes in hexon. <i>Virus Research</i> , 2014, 183, 67-74.	1.1	8
32	Neutralizing epitopes mapping of human adenovirus type 14 hexon. <i>Vaccine</i> , 2015, 33, 6659-6665.	1.7	8
33	A recombinant replication-defective human adenovirus type 3: A vaccine candidate. <i>Vaccine</i> , 2009, 27, 116-122.	1.7	7
34	Epitope mapping and cross-reactivity analysis of the monoclonal antibodies against hexon protein of human adenovirus type 3. <i>Virus Research</i> , 2009, 146, 58-65.	1.1	7
35	Epitope mapping and characterization of a neutralizing monoclonal antibody against human adenovirus type 3. <i>Virus Research</i> , 2013, 177, 189-193.	1.1	7
36	Analysis and solution of false-positives when testing CVA16 sera using an antibody assay against the EV71 virus. <i>Virus Research</i> , 2013, 176, 33-36.	1.1	6

#	ARTICLE	IF	CITATIONS
37	Mapping the epitope of neutralizing monoclonal antibodies against human adenovirus type 3. <i>Virus Research</i> , 2015, 208, 66-72.	1.1	6
38	Identification of adenovirus neutralizing antigens using capsid chimeric viruses. <i>Virus Research</i> , 2018, 256, 100-106.	1.1	6
39	Establishment and evaluation of a 30-minute detection method for SARS-CoV-2 nucleic acid using a novel ultra-fast real-time PCR instrument. <i>Journal of Thoracic Disease</i> , 2021, 13, 6866-6875.	0.6	6
40	Complete genome analysis of a novel E3-partial-deleted human adenovirus type 7 strain isolated in Southern China. <i>Virology Journal</i> , 2011, 8, 91.	1.4	5
41	Characterization of malleability and immunological properties of human adenovirus type 3 hexon hypervariable region 1. <i>Archives of Virology</i> , 2012, 157, 1709-1718.	0.9	5
42	Characterization of a replication-competent vector encoding DsRed based on a human adenovirus type 4 a-like strain. <i>Virus Research</i> , 2019, 270, 197662.	1.1	5
43	A Replication-Defective Influenza Virus Harboring H5 and H7 Hemagglutinins Provides Protection against H5N1 and H7N9 Infection in Mice. <i>Journal of Virology</i> , 2021, 95, .	1.5	5
44	A 10-Day-Old Murine Model of Coxsackievirus A6 Infection for the Evaluation of Vaccines and Antiviral Drugs. <i>Frontiers in Immunology</i> , 2021, 12, 665197.	2.2	5
45	Antigenic variability among two subtypes of human adenovirus serotype 7. <i>Virus Genes</i> , 2014, 49, 22-29.	0.7	4
46	Molecular evolution of human adenovirus type 16 through multiple recombination events. <i>Virus Genes</i> , 2019, 55, 769-778.	0.7	4
47	Design of an air isolation and purification (AIP) desk for medical use and characterization of its efficacy in ambient air isolation and purification. <i>Biosafety and Health</i> , 2020, 2, 169-176.	1.2	4
48	Development of two antigen-binding fragments to a conserved linear epitope of human adenovirus and their application in immunofluorescence. <i>PLoS ONE</i> , 2019, 14, e0219091.	1.1	3
49	An oral vaccine against CVA16 (Coxsackievirus A16) was developed by constructing a recombinant <i>Lactococcus lactis</i> . <i>Tropical Journal of Pharmaceutical Research</i> , 2020, 19, 927-932.	0.2	3
50	Infection and replication of human adenovirus type 3 possessing type 5 fiber protein in rodent cells. <i>Virus Research</i> , 2020, 279, 197886.	1.1	3
51	A novel method to diagnose the infection of enterovirus A71 in children by detecting IgA from saliva. <i>Journal of Medical Virology</i> , 2020, 92, 1059-1064.	2.5	2
52	A Sensitive and High-Throughput Flow Cytometry-Based Assay for Measuring Antibody Neutralization of Human Adenovirus Type 3. <i>Virologica Sinica</i> , 2021, 36, 537-544.	1.2	1
53	Design a pediatric isolation bed and characterization of its purification efficacy in ambient air. <i>Biosafety and Health</i> , 2021, 3, 172-172.	1.2	0
54	Similarity measurements of B cell receptor repertoire in baseline mice showed spectrum convergence of IgM. <i>BMC Immunology</i> , 2022, 23, 11.	0.9	0